1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Pfizer’s Big Bet On Arena Pays Off With First Phase III Win For Etrasimod In UC

Top-Line Readout Follows Recent $6.7bn Acquisition

 
• By Mandy Jackson

The company will present detailed data in the future, but top-line results show statistically significant improvement over placebo at 12 weeks in ulcerative colitis, an increasingly competitive market.

Casino green table with chips, money, play cards and dice
Pfizer turned over the first of two Phase III cards for etrasimod in ulcerative colitis • Source: Alamy

Pfizer Inc.’s $6.7bn bet on Arena Pharmaceuticals, Inc. appears to be paying off after the pharma giant reported on 23 March that the S1P receptor modulator etrasimod met the primary and all of the secondary endpoints in the first of two important Phase III clinical trials in ulcerative colitis. Results from a second, longer Phase III trial should soon follow, since Pfizer said they will be available by the end of the first quarter.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Camzyos nHCM Failure Could Open Door To Threat From Cytokinetics’ Aficamten

 
• By Alaric DeArment

BMS’s Phase III ODYSSEY-HCM study did not show statistical significance for either of its two primary endpoints.

Disappointing Asthma Phase II Results Take Wind Out Of Sanofi’s Amlitelimab

 
• By Andrew McConaghie

Sanofi’s OX40L candidate missed a Phase II primary endpoint, but the company believes it can still work in a sub-group of ‘heterogeneous inflammatory asthma’ patients.

Stock Watch: Disappointing ACC Share Price Reactions For AstraZeneca And Lilly

 
• By Andy Smith

The end of the American College of Cardiology conference was a prelude to a volatile trading week for most stocks. Even before Liberation Day, reactions to the conference announcements were not encouraging.

Pfizer’s Danuglipron Is Done, Sparking M&A Speculation

 
• By Jessica Merrill

The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.

More from R&D